

Anne-Claire Fougerousse, Jean-Luc Perrot, Ziad Reguiai, Edouard Begon, Laure Mery Bossard, Domitille Thomas Beaulieu, Diane Pourchot, Antoine Badaoui, Claire Boulard, Charlotte Fite, Ines Zaraa, Dominique Lons Danic, Jessica Beaziz, Josiane Parier, Guillaume Chaby, Anne Laure Liegeon, Alexandra Patchinsky, Axelle Bonhomme, Helene Martin, Amelie Schoeffler, Philippe Muller, Claire Poreaux, Caroline Jacobzone, Kevin Chassain, Claire-Alice De Salins, Jean-Benoît Monfort, Eric Estève, François Maccari, Pierre-André Becherel, for the OMCCI Group

## INTRODUCTION

Therapeutic armamentarium for atopic dermatitis (AD) has recently considerably evolved. Anticytokine (dupilumab, tralokinumab) and JAK inhibitors (JAKi) (baricitinib, upadacitinib) are currently available in France (upadacitinib and tralokinumab only with Temporary Authorization Use).

**Objective:** To compare patient's profile between anticytokine and JAKi treatments.

## MATERIALS And METHODS

OMCCI Cohort is a French prospective real-world multicentre study of chronic inflammatory skin diseases the objective of which is to determinate the impacts of these conditions on sufferer's lives. Inclusions started on December 2021 and are ongoing. In this preliminary analysis, we included patients who initiated dupilumab, tralokinumab, baricitinib or upadacitinib at baseline. The exclusion criteria was the presence of JAKi or anticytokine the 6 former months.

## RESULTS

Among the 358 patients with moderate-to-severe AD in the OMCCI cohort on 8th of June 2022, 206 fulfilled the inclusion criteria (dupilumab n=151, baricitinib n=52, upadacitinib n=2, tralokinumab n=1). Characteristics of patients are detailed in table 1. Patients initiating anticytokines at baseline had a wildspread disease (3.5 parts of the body with moderate to severe AD vs 2.3, p=0.007). Isolated head and neck AD was more frequent in patient initiating JAKi (9,3%) than anticytokines (3%). JAKi initiation decline from February 2022.

	Anticytokine (n=152)	JAKi (n=54)	P value
Mean age (years)	43 ± 18.6	32 ± 13.7	p<0.001
Sex female (%)	50.7	59.3	p=0,277
Marital status : single (%)	29.6	55.6	p=0,005
Mean EASI	21.4 ± 13.7	23.4 ± 13.6	p=0.279
Mean DLQI	13.3 ± 6.5	11.4 ± 5.6	p=0.054
Hospitalisation for AD the last 6 months (%)	7.9	3.7	p=0,364
Mean disease duration (years)	27.6±19.1	20.9 ± 14.1	p=0.026
Mean impact on daily life*	7.4 ± 1.9	7.3 ± 1.6	p=0.381
Mean impact on family life*	6.0 ± 2.8	5.3 ± 2.7	p=0.049
Mean impact on professional life*	6.20± 3.3	7 ± 2.4	p=0.171
Mean score of physical dimension of SF12	47.21 ± 9.32	51.80 ± 5.95	p=0.002
Mean score of mental dimension of SF12	35.58 ± 10.66	38.28 ± 10.83	p=0.123

Table 1: Patients characteristics

\*VAS: visual analogic scale from 0 to 10

## CONCLUSION

Patients initiating anticytokines were older, had a more wildspread disease with higher impact on family life and on physical health according to SF12 score. JAKi were initiated in younger patients This can be explained by the safety profile of JAKi. Revision process of JAKi's safety by health authorities had impact on cinetic of JAKi's initiation (diminution from February 2022). These preliminary results highlight two profiles of AD patients according to treatment mostly guided by the controversial safety profile of JAKi.